NCT06466135 - Study of WAL0921 in Patients With Glomerular Kidney Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

March 31, 2026

Conditions

Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change DiseasePrimary Immunoglobulin A NephropathyPrimary Membranous Nephropathy

Interventions

DRUG

WAL0921

Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.

DRUG

Placebo

Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.

Trial Locations (9)

2145

ACTIVE_NOT_RECRUITING

Westmead Hospital, Westmead

3021

ACTIVE_NOT_RECRUITING

Western Health Sunshine Hospital, St Albans

33321

RECRUITING

D & H Tamarac Research Center, Tamarac

80012

RECRUITING

Colorado Kidney and Vascular Care, Denver

DE22 3NE

NOT_YET_RECRUITING

Royal Derby Hospital, Derby

LE1 7RH

NOT_YET_RECRUITING

College of Life Sciences, University of Leicester, Leicester

E1 2ES

NOT_YET_RECRUITING

Barts Health NHS Trust, London

M13 9WL

NOT_YET_RECRUITING

Manchester University NHS Foundation Trust, Manchester

M6 8HD

NOT_YET_RECRUITING

Salford Royal NHS Foundation Trust, Salford